Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Regeneron Shows Proof Of Concept For Novel Cholesterol Drug

Executive Summary

An investigational hypolipemic product from Regeneron Pharmaceuticals with a novel mechanism of action appears to have great promise when used in addition to current therapies in familial hypercholesterolemia patients, suggest early data from a small study, but many questions remain.

Advertisement

Related Content

Regeneron Emphasizes Pipeline Promise As Eylea Pricing Pressure Builds

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register